liver cancer

[iScience] Scientists generated a doxycycline inducible MHC-I and II antigen expressing HCC cell line which allowed them to investigate tumor antigen specific T cell response in two non-alcoholic fatty liver disease (NAFLD) mouse models.

[Molecular Cancer Research] Investigators found that the acidic tumor microenvironment contributed to lipid accumulation in liver cancer by activating the PI3K/AKT signaling pathway and promoting SCD1-PPARα binding.

[Heliyon] Researchers investigated melatonin's antitumor molecular mechanisms to inhibit the proliferation of HepG2 cells.

[Lyell Immunopharma, Inc.] Lyell Immunopharma, Inc. announced that the US FDA has cleared an Investigational New Drug (IND) application to initiate a Phase I clinical trial for LYL132, an investigational T-cell receptor therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1 that the company is developing in collaboration with GSK.

[Cell Reports] The authors showed that mitochondrial DNA of the normal liver shaped tumor progression, histology, and immune environment prior to the acquisition of oncogenic mutation.

[Nature Communications] Using hepatocyte-, hepatoblast- and ductal cell-derived organoids, investigators demonstrated that the differentiation defects and lipid alterations were, in part, cell-autonomous.